Arturo LoAIza-Bonilla, Network Chief of Hematology and Oncology at St. Luke’s University Health Network, Co-Founder and Chief Medical AI Officer (CMAIO) of Massive Bio, shared a post on LinkedIn:
“Speaking to the promise and practical friction of digital health tools, Arturo LoAIza-Bonilla MD, associate professor of medicine, Temple University – Lewis Katz School of Medicine, and network chief of hematology and oncology, St. Luke’s University Health Network, discussed remote consent and telemedicine-enabled trial visits.
He argued that comanagement of the standard of care within a multisite network is already FDA permissible but underutilized, largely due to institutional inertia. He called on sponsors to build budget templates that explicitly account for social determinants of health, noting that many Hispanic patients he offers trials to decline not because of cultural reticence but because missing work is economically impossible.
‘Stop talking about disparities,’ Loaiza-Bonilla said. ‘Invest the money to do something about it.”
Other articles about FDA on OncoDaily.